UniQure shares surge as FDA aligns on accelerated approval pathway for AMT-130 in Huntington’s disease

Shares of UniQure soared, more than doubling after the U.S. Food and Drug Administration (FDA) agreed on key elements of an accelerated approval pathway for AMT-130, an investigational gene therapy for Huntington’s disease. This breakthrough positions the company to potentially expedite regulatory approval without the need for additional pre-submission studies.

UniQure’s stock hit a 52-week high, trading at $16.13, following the announcement. The FDA confirmed that data from the ongoing Phase I/II studies could serve as the primary basis for a Biologics License Application (BLA) under the accelerated approval pathway. The agency also recognized the composite Unified Huntington’s Disease Rating Scale (cUHDRS) as an intermediate clinical endpoint, marking a significant milestone in Huntington’s disease treatment.

Regenerative Medicine Designation Boosts Prospects

UniQure received the FDA’s Regenerative Medicine designation for AMT-130 in May 2024, underscoring the therapy’s potential to meet unmet medical needs in Huntington’s disease treatment. The designation follows interim Phase I/II study results showing dose-dependent slowing of disease progression and reductions in neurofilament light chain (NfL) levels, a biomarker for neurodegeneration.

At a recent meeting with the FDA, UniQure officials discussed the statistical analysis plan and technical manufacturing requirements for their BLA, with plans to reconvene with the FDA in early 2025. Dr. Walid Abi-Saab, UniQure’s Chief Medical Officer, expressed optimism, noting that the collaboration reflects the robust data and mutual commitment to advancing a therapy that could dramatically improve the lives of patients with this debilitating condition.

Promising Clinical Developments

UniQure’s U.S.-based Phase I/II study involves 26 patients with early manifest Huntington’s disease. Participants were randomized into treatment groups receiving low-dose or high-dose AMT-130 or undergoing a sham surgical procedure. Preliminary findings showed promising improvements, particularly in treated groups, as evidenced by reduced NfL levels and slowed disease progression, solidifying the case for its accelerated approval pathway.

The European Phase Ib/II study enrolled 13 patients, with a third cohort now underway to assess the combined impact of AMT-130 with immunosuppression. The therapy employs MRI-guided, convection-enhanced delivery directly into the striatum, leveraging cutting-edge gene therapy advancements.

Gene Therapy: A Transformative Future

UniQure’s advancements reflect a broader revolution in gene therapy advancements. With their successful launch of a therapy for hemophilia B, UniQure has established a strong pipeline addressing severe conditions such as ALS, Fabry disease, and temporal lobe epilepsy. For Huntington’s disease treatment, AMT-130 represents a beacon of hope, potentially delivering long-lasting therapeutic benefits from a single treatment.

As UniQure continues to refine AMT-130’s development, the biotechnology community awaits further updates on its journey through the regulatory landscape. With FDA clinical alignment in place, the company is poised to drive forward a pioneering therapy that could redefine standards for treating neurodegenerative diseases.